Psicodermatologa Preliminaresybibliografa
Psicodermatologa Preliminaresybibliografa
Psicodermatologa Preliminaresybibliografa
net/publication/332652866
CITATIONS READS
3 4,767
2 authors, including:
Julio Torales
Universidad Nacional de Asunción
547 PUBLICATIONS 5,105 CITATIONS
SEE PROFILE
All content following this page was uploaded by Julio Torales on 28 April 2019.
ISBN 978-99953-67-21-3
Diseño: Quadrivium
Impreso en Imprenta Salesiana | Tirada: 300 ejemplares
Gisela D’Atri
Karina Di Benedetto
Patricia Fretes
Lourdes González
Sandra González
Rubén López
Karina Malvido
Osvaldo Melgarejo
Rodrigo Navarro
capítulo 5 Tricotilomanía107
5.1. Introducción 107
5.2. Concepto 108
5.2.1. Epidemiología 108
5.3. Etiopatogenia y aspectos psicodermatológicos 109
5.3.1. Aspectos psicopatológicos 110
5.3.2. Factores desencadenantes 111
5.4. Clínica 113
5.4.1. Histopatología 114
5.5. Diagnóstico y diferenciales 115
5.5.1. Características asociadas
que apoyan el diagnóstico 116
5.5.2. Diferenciales psiquiátricos 117
5.5.3. Diferenciales dermatológicos 118
5.5.4. Comorbilidades 118
5.6. Curso y pronóstico 119
5.7. Tratamiento 119
5.7.1. Evaluación 119
5.7.2. Psicoterapia 121
5.7.3. Farmacoterapia dermatológica 122
5.7.4. Psicofarmacoterapia 122
5.7.5. Acercándonos a un paciente con tricotilomanía 124
5.8. Puntos clave 125
5.9. Bibliografía 126
capítulo 9 Psoriasis173
9.1. Introducción 173
9.2. Concepto 173
9.2.1. Epidemiología 174
9.3. Etiopatogenia y aspectos psicodermatológicos 175
9.3.1. Psicodermatología 175
9.3.2. Etiopatogenia 180
9.4. Clínica 185
9.5. Diagnóstico y diferenciales 187
9.5.1. Diferenciales dermatológicos 187
9.5.2. Comorbilidades psiquiátricas 187
9.6. Curso y pronóstico 188
9.7. Tratamiento 188
9.7.1. Dermatológico 188
9.7.2. Fármacos y psicoterapia 189
9.8. Puntos clave 192
9.9. Bibliografía 194
capítulo 11 Acné219
11.1. Introducción 219
11.2. Concepto 219
11.2.1. Epidemiología 220
11.3. Etiopatogenia y aspectos psicodermatológicos 220
11.3.1. Psicodermatología 221
11.4. Clínica 222
11.4.1. Lesiones no inf lamatorias (de retención) 222
11.4.2. Lesiones inf lamatorias 223
11.4.3. Clasificación 224
11.4.4. Formas especiales 225
11.4.5. Erupciones acneiformes 225
11.5. Diagnóstico y diferenciales 227
11.5.1. Diagnóstico diferencial 227
11.6. Curso y pronóstico 229
11.7. Tratamiento 229
11.7.1. Tratamiento dermatológico 230
11.7.2. Tratamiento psiquiátrico y psicológico 233
11.8. Puntos clave 234
11.9. Bibliografía 235
capítulo 12 Rosácea237
12.1. Introducción 237
12.2. Concepto 237
12.2.1. Epidemiología 238
12.3. Etiopatogenia y aspectos psicodermatológicos 238
12.3.1. Psicodermatología 241
12.4. Clínica 242
12.5. Diagnóstico y diferenciales 245
12.5.1. Diagnóstico diferencial 246
12.6. Curso y pronóstico 248
12.7. Tratamiento 248
12.7.1. Tratamiento dermatológico 249
12.7.2. Tratamiento psiquiátrico y psicológico 251
12.8. Puntos clave 253
12.9. Bibliografía 254
24
Esta obra nos ayudará a comprender y manejar con éxito a los pacientes
“psicodermatológicos”, que en un primer momento pudieran parecer difí-
ciles de abordar. Mediante el conocimiento de su clasificación y la familia-
rización con las diferentes opciones terapéuticas que han demostrado ser
eficaces y que se presentan a lo largo de los diferentes capítulos, aprendere-
mos a tratar mejor a nuestros pacientes y a conseguir una mayor satisfac-
ción personal y profesional.
25
La Dra. Estela Malatesta es la otra codirectora de este libro y también auto-
ra de diversos capítulos. Médica (Universidad de Buenos Aires, Argentina).
Especialista en Dermatología (Universidad de Buenos Aires, Argentina).
Especialista en Psiquiatría (Universidad Maimónides, Argentina). Especia-
lista en Clínica Médica (Ministerio de Salud de la Nación, Argentina). Más-
ter en Neurociencias (Universidad Maimónides, Argentina). Es presidenta
y cofundadora de la Academia de Dermatología y Psiquiatría Argentina
(ADEPSI Argentina). Directora y docente de la Diplomatura Universitaria
en Psicodermatología (ADEPSI Argentina). Presidenta honoraria y acadé-
mica de honor de la Academia de Dermatología y Psiquiatría Paraguaya
(ADEPSI Paraguay). Miembro de la Comisión de Psicodermatología de la
Sociedad Latinoamericana de Psoriasis (SOLAPSO). Trabaja como médica
de planta (Psiquiatría, Psicodermatología) del Centro de Salud Mental “Dr.
Arturo Ameghino” (Ciudad Autónoma de Buenos Aires, Argentina). Ade-
más, es directora del Primer Curso de Psicodermatología del Gobierno de
la Ciudad de Buenos Aires: “Psicodermatología: la piel en la dinámica de los
fenómenos somato-psíquicos”.
26
El libro “Psicodermatología: una actualización diagnóstica y terapéutica
de las entidades clínicas más frecuentes” está destinado a ser el manual
de referencia de los profesionales de la Dermatología, la Psiquiatría y la
Psicología para el abordaje integrativo de los diversos aspectos psicológi-
cos y psiquiátricos asociados a la enfermedad dermatológica, tanto en sus
enfoques diagnósticos como terapéuticos, y a ser una obra de consulta im-
portante a tener en nuestras bibliotecas, no solo personales, sino de todos
los servicios de salud, escuelas de Medicina y Universidades.
Servando E. Marrón, MD
Doctor en Medicina y Cirugía, Dermatólogo, Hospital
Universitario Miguel Servet, Zaragoza, España
Investigador Principal del Grupo Aragonés de Investigación
en Psicodermatología (GAI+PD), Zaragoza, España
Coordinador Nacional del Grupo Español de Investigación en
Dermatología y Psiquiatría (GEDEPSI) de la Academia Española
de Dermatología y Venereología (AEDV), Madrid, España
Miembro Titular del Colegio Ibero-Latinoamericano
de Dermatología (CILAD)
27
PRESENTACIÓN
Ha sido un gran placer escribir este libro y plasmar en sus páginas lo tra-
bajado desde hace varios años en el campo de la Psicodermatología. Todos
los autores hemos estado involucrados, de alguna u otra manera, en esta
fascinante área de la ciencia, donde se pueden observar, de primera mano,
las íntimas interacciones entre piel, mente y cerebro, que no son otra cosa
que el ref lejo de la propia complejidad del ser humano. Es por ello que la
publicación de esta obra se nos hizo casi obligatoria, a fin de poder compar-
tir evidencia y experiencia clínica en el manejo de este grupo de pacientes.
28
¿No será lo corporal un acontecer y no una sustancia?
Alberto Girri (1919-1991), poeta argentino
1.8. Bibliografía
48
15. Torales J, Di Martino B. Psychodermatology: mind the skin.
Psychodermatology: mind the skin. Telangana Journal of Psychiatry
2016;2(1):5-7. URL.
16. Walker C, Papadopoulos L. Psychodermatology: The Psychological
Impact of Skin Disorders. Cambridge University Press: New York; 2005.
17. Gilbert SF, Barresi MJF. Developmental biology. 11th edition. Sunderland,
Massachusetts: Sinauer Associates, Inc; 2016.
18. Odlaug BL, Hampshire A, Chamberlain SR, Grant JE. Abnormal brain
activation in excoriation (skin-picking) disorder: evidence from an
executive planning fMRI study. Br J Psychiatry. 2016;208(2):168-174.
https://doi.org/10.1192/bjp.bp.114.155192
19. Grant JE, Odlaug BL, Hampshire A, Schreiber LR, Chamberlain SR.
White matter abnormalities in skin picking disorder: a diffusion tensor
imaging study. Neuropsychopharmacology. 2013;38(5):763-769. https://
doi.org/10.1038/npp.2012.241
20. Harth W, Gieler U, Kusnir D, Tausk FA. Clinical management in
psychodermatology. Berlin: Springer; 2009.
21. Lowry CL, Shah R, Fleming C, Taylor R, Bewley A. A study of
service provision in psychocutaneous medicine. Clin Exp Dermatol.
2014;39(1):13-18. https://doi.org/10.1111/ced.12235
22. Panconesi E. Notas introductorias sobre la clasificación de las
modalidades clínicas en dermatología psicosomática. En: En: Grimalt
F, Cotterill J, editores. Dermatología y Psiquiatría. Madrid: Aula Médica
Ediciones; 2002. p. 127-132.
23. Serón D, Calderón H. Actualización en psicodermatología. Rev Hosp
Clín Univ Chile 2015;26:42-50. URL.
24. Koo J, Lebwohl A. Psychodermatology: the mind and skin connection.
Am Fam Physician 2001;64(11):1873-1878. URL.
25. Torales J. Delusional Infestations. En: Bhugra D, Malhi G, editores.
Troublesome disguises: Managing challenging disorders in Psychiatry.
2nd ed. London: Wiley Blackwell; 2015. p. 252-61.
26. Bewley A, Taylor RE, Reichenberg JS, Magid M. Practical
Psychodermatology. 1st edition. Chichester, West Sussex, UK: Wiley-
Blackwell; 2014.
27. Mohandas P, Bewley A, Taylor R. Dermatitis artefacta and artefactual
skin disease: the need for a psychodermatology multidisciplinary team
to treat a difficult condition. Br J Dermatol 2013;169(3):600-606. https://
doi.org/10.1111/bjd.12416
28. Pan W, Zhou H. Integrative Medicine: A Paradigm Shift in Clinical
Practice. Int. j. integr. med. 2013;1(21):1-6.
49
29. Azambuja RD. The need of dermatologists, psychiatrists and
psychologists joint care in psychodermatology. An Bras Dermatol.
2017;92(1):63-71. https://doi.org/10.1590/abd1806-4841.20175493
30. Van Moffaert M. Training future dermatologists in psychodermatology.
Gen Hosp Psychiatry. 1986;8(2):115-118. URL.
31. Renshaw DC. Sex and the dermatologist. Int J Dermatol. 1980;19(8):469-
471. URL.
32. Gupta MA, Gupta AK, Ellis CN, Koblenzer CS. Psychiatric Evaluation of
the Dermatology Patient. Dermatol Clin. 2005;23(4):591-599. https://doi.
org/10.1016/j.det.2005.05.005
33. Ghosh S, Behere RV, Sharma P, Sreejayan K. Psychiatric evaluation in
dermatology: an overview. Indian J Dermatol. 2013;58(1):39-43. https://
doi.org/10.4103/0019-5154.105286
34. Osman OT, Mufaddel A, Almugaddam F, Augusterfer EF. The psychiatric
aspects of skin disorders. Expert Rev Dermatol. 2011;6(2):195-209. https://
doi.org/10.1586/edm.11.10
35. Buljan D, Buljan M, Zivković MV, Situm M. Basic aspects of
psychodermatology. Psychiatr Danub. 2008;20(3):415-418. URL.
36. Shenefelt PD. Update on psychodermatological disorders. Expert Rev
Dermatol. 2010;5(1):95-107. https://doi.org/10.1586/edm.09.62
50
2.6. Bibliografía
61
3.9. Bibliografía
77
14. Trabert W. 100 years of delusional parasitosis. Meta-analysis of
1,223 case reports. Psychopathology 1995;28(5):238-246. https://doi.
org/10.1159/000284934
15. Lyell A. Delusions of parasitosis. Journal of the American Academy
of Dermatology 1983;8(6):895-897. https://doi.org/10.1016/S0190-
9622(83)80024-3
16. Le L, Gonski PN. Delusional parasitosis mimicking cutaneous infestation
in elderly patients. Med J Aust 2003; 179(4): 209-10. URL.
17. Hinkle NC. Ekbom syndrome: the challenge of ‘‘invisible bug”
infestations. Annu Rev Entomol. 2010;55:77-94. https://doi.org/10.1146/
annurev.ento.54.110807.090514.
18. Huber M, Karner M, Kirchler E, Lepping P, Freudenmann RW. Striatal
lesions in delusional parasitosis revealed by magnetic resonance
imaging. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(8):1967-
1971. https://doi.org/10.1016/j.pnpbp.2008.09.014
19. Millard LG, Millard J. Psychocutaneous disorders. In: Burns T,
Breathnach S, Cox N, Griffiths C, eds. Rook’s Textbook of Dermatology.
8th ed. Oxford: Wiley-Blackwell; 2010. p. 3281-3284.
20. Freudenmann RW, Kühnlein P, Lepping P, Schönfeldt-Lecuona C.
Secondary delusional parasitosis treated with paliperidone. Clin
Exp Dermatol. 2009 Apr;34(3):375-377. https://doi.org/10.1111/j.1365-
2230.2008.02954.x
21. Freudenmann RW, Schönfeldt-Lecuona C, Lepping P. Primary delusional
parasitosis treated with olanzapine. Int. Psychogeriatr. 2007;19(6):1161-
1168. https://doi.org/10.1017/S1041610207004814
22. Kim C, Kim J, Lee M, Kang M. Delusional parasitosis as ‘folie a deux’.
J Korean Med Sci. 2003 Jun;18(3):462-465. https://doi.org/10.3346/
jkms.2003.18.3.462
23. Harth W, Hermes B, Freudenmann RW. J Dtsch Dermatol Ges.
2010;8(4):234-242. https://doi.org/10.1111/j.1610-0387.2009.07219.x
24. Wykoff RF. Delusions of parasitosis: a review. Rev. Infect. Dis. 1987;
9(3):433-437. URL.
25. Lee WR. Matchbox sign. Lancet. 1983;2(8347):457-458. https://doi.
org/10.1016/S0140-6736(83)90423-3
26. Goddard J. Analysis of 11 cases of delusions of parasitosis reported to
the Mississippi Department of Health. South. Med. J. 1995; 88(8):837-839.
URL.
27. Monk BE, Rao YJ. Delusions of parasitosis with fatal outcome. Clin. Exp.
Dermatol. 1994;19(4):341-342. URL.
78
28. Torales J. Delirio de infestación y folie à deux [Monografía]. San Lorenzo:
Universidad Nacional de Asunción; 2016.
29. Cordeiro Júnior Q, Pereira Corbett CE. Delírio de infestação parasitária
e folie à deux. Relato de caso. Arq Neuropsiquiatr 2003;61(3-B):872-875.
https://doi.org/10.1590/S0004-282X2003000500033
30. Prološčić J, Vučić Peitl M, Peitl V, Grahovac T. Morgellons disease and/
or psychosis. European Psychiatry 2012;27(1):885. https://doi.org/10.1016/
S0924-9338(12)75052-6
31. Dewan P, Miller J, Musters C, Taylor RE, Bewley AP. Delusional infestation
with unusual pathogens: a report of three cases. Clin Exp Dermatol.
2011;36(7):745-748. https://doi.org/10.1111/j.1365-2230.2011.04086.x
32. Hylwa SA, Foster AA, Bury JE, Davis MD, Pittelkow MR, Bostwick,
JM. Delusional infestation is typically comorbid with other psychiatric
diagnoses: review of 54 patients receiving psychiatric evaluation at Mayo
Clinic. Psychosomatics. 2012;53(3):258-265. https://doi.org/10.1016/j.
psym.2011.11.003
33. Freudenmann RW. Delusions of parasitosis: An up-to-date
review. Fortschr Neurol Psychiatr. 2002;70(10):531-541. https://doi.
org/10.1055/s-2002-34666
34. Freudenmann RW, Kölle M, Huwe A, Luster M, Reske SN, Huber
M et al. Delusional infestation: neural correlates and antipsychotic
therapy investigated by multimodal neuroimaging. Prog
Neuropsychopharmacol Biol Psychiatry. 2010;34(7):1215-22. https://doi.
org/10.1016/j.pnpbp.2010.06.022
35. Slaughter JR, Zanol K, Rezvani H, Flax J. Psychogenic parasitosis. A case
series and literature review. Psychosomatics 1998;39(6):491-500. https://
doi.org/10.1016/S0033-3182(98)71281-2
36. Zanol K, Slaughter J, Hall R. An approach to the treatment of psychogenic
parasitosis. Int. J. Dermatol. 1998;37(1):56-63. URL.
37. Zomer SF, De Wit RF, Van Bronswijk JE, Nabarro G, Van Vloten
WA. Delusions of parasitosis. A psychiatric disorder to be treated by
dermatologists? An analysis of 33 patients. Br. J. Dermatol. 1998;138(6):
1030-1032. URL.
79
4.9. Bibliografía
102
13. Wilson E. Lectures on Dermatology. Delivered in the Royal College of
Surgeons of England, 1874-1875. London: J and A Churchil; 1875.
14. Lochner C, Roos A, Stein DJ. Excoriation (skin-picking) disorder: a
systematic review of treatment options. Neuropsychiatr Dis Treat.
2017;13:1867-1872. https://doi.org/10.2147/NDT.S121138
15. Koblenzer CS, Gupta R. Neurotic excoriations and dermatitis artefacta.
Semin Cutan Med Surg. 2013;32(2):95-100. URL
16. American Psychiatric Association. Diagnostic and Statistical Manual
of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric
Publishing; 2013.
17. Lochner C, Simeon D, Niehaus DJ, Stein DJ. Trichotillomania and skin-
picking: a phenomenological comparison. Depress Anxiety. 2002;15(2):83-
86. URL.
18. Keuthen NJ, Deckersbach T, Wilhelm S, Hale E, Fraim C, Baer L et al.
Repetitive skin-picking in a student population and comparison with a
sample of self-injurious skin-pickers. Psychosomatics. 2000;41(3):210-215.
https://doi.org/10.1176/appi.psy.41.3.210
19. Hayes SL, Storch EA, Berlanga L. Skin picking behaviors: an examination
of the prevalence and severity in a community sample. J Anxiety Disord.
2009;23(3):314-319. https://doi.org/10.1016/j.janxdis.2009.01.008
20. Keuthen NJ, Koran LM, Aboujaoude E, Large MD, Serpe RT. The
prevalence of pathologic skin picking in US adults. Compr Psychiatry.
2010;51(2):183-186. https://doi.org/10.1016/j.comppsych.2009.04.003
21. Keuthen NJ, Jameson M, Loh R, Deckersbach T, Wilhelm S, Dougherty
DD. Open-label escitalopram treatment for pathological skin picking.
Int Clin Psychopharmacol. 2007;22(5):268-274. https://doi.org/10.1097/
YIC.0b013e32809913b6
22. Odlaug BL, Grant JE. Phenomenology and epidemiology of pathological
skin picking. En: Grant JE, Potenza MN, editores. The Oxford Library of
Psychology: Oxford Handbook of Impulse Control Disorders. New York,
USA: Oxford University Press; 2011. p. 186-195.
23. Ehsani AH, Toosi S, Mirshams Shahshahani M, Arbabi M,
Noormohammadpour P. Psycho-cutaneous disorders: an epidemiologic
study. J Eur Acad Dermatol Venereol. 2009;23(8):945-947. https://doi.
org/10.1111/j.1468-3083.2009.03236.x
24. Wilhelm S, Keuthen NJ, Deckersbach T, Engelhard IM, Forker AE, Baer L
et al. Self-injurious skin picking: clinical characteristics and comorbidity.
J Clin Psychiatry. 1999;60(7):454-459. URL.
103
25. Grant JE, Williams KA, Potenza MN. Impulse-control disorders in
adolescent psychiatric inpatients: co-occurring disorders and sex
differences. J Clin Psychiatry. 2007;68(10):1584-1592. URL.
26. Stein D, Lochner C. Psychobiology of hair-pulling disorder
(trichotillomania) and skin-picking disorder. En: Grant J, Stein D, Woods
D, Keuthen N, editors. Trichotillomania, skin picking and other body-
focused repetitive behaviors. Washington DC: American Psychiatric
Publishing; 2012. p. 65-80.
27. Feusner JD, Hembacher E, Phillips KA. The mouse who couldn’t stop
washing: pathologic grooming in animals and humans. CNS Spectr.
2009;14(9):503-513. URL.
28. Schroeder SR1, Oster-Granite ML, Berkson G, Bodfish JW, Breese
GR, Cataldo MF. Self-injurious behavior: gene-brain-behavior
relationships. Ment Retard Dev Disabil Res Rev. 2001;7(1):3-12. https://
doi.org/10.1002/1098-2779(200102)7:1<3::AID-MRDD1002>3.0.CO;2-#
29. Torales Benítez J, Cuadrado Manías J, Capurro MH. Psicobiología y
psicopatología del trastorno de excoriación. En: Torales Benítez J, editor.
El Trastorno de Excoriación: de la emoción a la lesión. 1ª ed. Asunción:
EFACIM; 2014. p. 63-70.
30. Teng EJ, Woods DW, Twohig MP, Marcks BA. Body-focused repetitive
behavior problems. Prevalence in nonreferred population and differenc-
es in perceived somatic activity. Behav Modif 2002;26(3):340-360. https://
doi.org/10.1177/0145445502026003003
31. Woods DW. Introduction to the special issue on repetitive behavior
problems. Behav Modif 2002;26(3):315-319. https://doi.org/10.1177/01454
45502026003001
32. Torales J, Viola L, Arce A. Guía Esencial de Tricotilomanía Pediátrica. 1ª
ed. Asunción: EFACIM; 2014.
33. Rodríguez-Pichardo A. Excoriaciones neuróticas. En: Grimalt F, Cotterill
J, editores. Dermatología y Psiquiatría. Madrid: Aula Médica Ediciones;
2002. p. 165-170.
34. Torales Benítez J, Rodríguez Masi M, Riego Meyer V. Clínica del trastorno
de excoriación. En: Torales Benítez J, editor. El Trastorno de Excoriación:
de la emoción a la lesión. 1ª ed. Asunción: EFACIM; 2014. p. 53-62.
35. Flessner CA, Woods DW. Phenomenological characteristics, social
problems and the economic impact associated with chronic skin picking.
Behav Modif30(6):944-963, 2006. https://doi.org/10.1177/0145445506294083
36. Odlaug BL, Grant JE. Clinical characteristics and medical complications
of pathologic skin picking. Gen Hosp Psychiatry. 2008;30(1):61-66. https://
doi.org/10.1016/j.genhosppsych.2007.07.009
104
37. Grant JE, Odlaug BL, Kin SW. Lamotrigine treatment of pathologic skin
picking: an open-study. J Clin Psychiatry 2007;68(9):1384-1391. URL.
38. Arnold LM1, McElroy SL, Mutasim DF, Dwight MM, Lamerson CL,
Morris EM. Characteristics of 34 adults with psychogenic excoriation. J
Clin Psychiatry 1998;59(10):509-514. URL.
39. Torales Benítez J, Rodríguez Marín H. Diagnóstico y evaluación del
trastorno de excoriación. En: Torales Benítez J, editor. El Trastorno de
Excoriación: de la emoción a la lesión. 1ª ed. Asunción: EFACIM; 2014. p.
79-90.
40. Brítez Cantero J, Torales Benítez J, Valenzuela Hermosa C, Chávez
ME. Trastornos somatomorfos. En: Arce Ramírez A, Torales Benítez J,
editores. El Libro Azul de la Psiquiatría. Asunción: EFACIM; 2012. p. 185-
203.
41. Torales J, Arce A, Bolla L, González L, Di Martino B, Rodríguez M,
Knopfelmacher O. Delirio parasitario dermatozoico. Reporte de un caso.
An. Fac. Cienc. Méd. 2011;44(2):81-87. URL.
42. Flessner C. Diagnosis and comorbidity. En: Grant J, Stein D, Woods D,
Keuthen N, editores. Trichotillomania, skin picking and other body-
focused repetitive behaviors. Washington DC: American Psychiatric
Publishing; 2012. p. 83-96.
43. Grant JE, Odlaug BL, Chamberlain SR, Keuthen NJ, Lochner C, Stein DJ.
Skin Picking Disorder. Am J Psychiatry 2012; 169(11):1143-1149. https://
doi.org/doi/10.1176/appi.ajp.2012.12040508
44. Snorrason I, Olafsson RP, Flessner CA, Keuthen NJ, Franklin ME, Woods
DW. Skin Picking Scale-Revised: Factor structure and psychometric
properties. J Obsessive Compuls Relat Disord 2012;1:133-137. https://doi.
org/10.1016/j.jocrd.2012.03.001
45. Keuthen N, Siev J, Reese H. Assessment of trichotillomania, pathological
skin picking, and stereotypic movement disorder. En: Grant J, Stein
D, Woods D, Keuthen N, editores. Trichotillomania, skin picking and
other body-focused repetitive behaviors. Washington DC: American
Psychiatric Publishing; 2012. p. 129-150.
46. Torales Benítez J, Girala Salomón N. Farmacoterapia del trastorno de
excoriación. En: Torales Benítez J, editor. El Trastorno de Excoriación:
de la emoción a la lesión. 1ª ed. Asunción: EFACIM; 2014. p. 101-108.
47. Chamberlain SR, Fineberg NA, Odlaug BL. Pharmacotherapy. En: Grant
J, Stein D, Woods D, Keuthen N, editores. Trichotillomania, skin picking
and other body-focused repetitive behaviors. Washington DC: American
Psychiatric Publishing; 2012. p. 205-221.
105
48. Grant JE, Chamberlain SR, Redden SA, Leppink EW, Odlaug BL, Kim SW.
N-Acetylcysteine in the treatment of excoriation disorder: a randomized
clinical trial. JAMA Psychiatry. 2016;73(5):490-6. https://doi.org/10.1001/
jamapsychiatry.2016.0060
49. Torales J, Barrios I, Villalba J. Alternative Therapies for Excoriation (Skin
Picking) Disorder: A Brief Update. Adv Mind Body Med. 2017;31(1):10-13.
URL.
106
5.9. Bibliografía
126
14. Zuchner S, Cuccaro ML, Tran-Viet KN, Cope H, Krishnan RR, Pericak-
Vance MA et al. SLITRK1 mutations in trichotillomania. Mol Psychiatry.
2006;11(10):887-889. https://doi.org/10.1038/sj.mp.4001865
15. Bienvenu OJ, Wang Y, Shugart YY, Welch JM, Grados MA, Fyer AJ et al.
Sapap3 and pathological grooming in humans: Results from the OCD
collaborative genetics study. Am J Med Genet B Neuropsychiatr Genet.
2009;150B(5):710-720. https://doi.org/10.1002/ajmg.b.30897
16. Rodríguez-Pichardo A. Tricotilomanía. En: Grimalt F, Cotterill J,
editores. Dermatología y Psiquiatría. Madrid: Aula Médica Ediciones;
2002. p. 203-209.
17. Mannino FV, Delgado RA. Trichotillomania in children. A Review. Am J
Psychiatry 1969;126(4): 505-511. https://doi.org/10.1176/ajp.126.4.505
18. Roberts S, O’Connor K, Bélanger C. Emotion regulation and other
psychological models for body-focused repetitive behaviors. Clin Psychol
Rev. 2013;33(6):745-762. https://doi.org/10.1016/j.cpr.2013.05.004
19. Shusterman A, Feld L, Baer L, Keuthen N. Affective regulation in
trichotillomania: Evidence from a large-scale internet survey. Behav Res
Ther. 2009;47(8):637-644. https://doi.org/10.1016/j.brat.2009.04.004
20. O’Connor K, Brisebois H, Brault M, Robillard S, Loiselle J. Behavioral
activity associated with onset in chronic tic and habit disorder. Behav
Res Ther. 2003; 41(2):241-249. URL.
21. Woods DW, Flessner C, Franklin ME, Wetterneck CT, Walther MR,
Anderson ER et al. Understanding and treating trichotillomania: what we
know and what we don’t know. Psychiatr Clin North Am. 2006;29(2):487-
501. https://doi.org/10.1016/j.psc.2006.02.009
22. Saraswat A. Child abuse and trichotillomania. BMJ. 2005;330(7482):83-84.
https://doi.org/10.1136/bmj.330.7482.83
23. Keuthen NJ, O’Sullivan RL, Hayday CF, Peets KE, Jenike MA, Baer L The
relationship of menstrual cycle and pregnancy to compulsive hairpulling.
Psychother Psychosom 1997;66(1):33-37. https://doi.org/10.1159/000289103
George S, Moselhy H. Cocaine-induced trichotillomania. Addiction
2005;100(2):255-256. https://doi.org/10.1111/j.1360-0443.2004.00955.x
24. Franklin ME, Edson AL, Ledley DA, Cahill SP. Behavior therapy for
pediatric trichotillomania: a randomized controlled trial. J Am Acad
Child Adolesc Psychiatry. 2011;50(8):763-771. https://doi.org/10.1016/j.
jaac.2011.05.009
25. Torales J, Barrios I. La psicopatología tras un tricobezoar. Rev ANACEM
2017; 11(1): [Epub ahead of print].
26. Hautmann G, Hercogova J, Lotti T. Trichotillomania. J Am Acad
Dermatol 2002;46(6):807-821. URL.
127
27. Lochner C, Seedat S, du Toit PL, Nel DG, Niehaus DJ, Sandler
R et al. Obsessive-compulsive disorder and trichotillomania: a
phenomenological comparison. BMC Psychiatry 2005;5:2. https://doi.
org/10.1186/1471-244X-5-2
28. Stefanato CM. Histopathology of alopecia: a clinicopathological
approach to diagnosis. Histopathology 2010;56(1):24-38. https://doi.
org/10.1111/j.1365-2559.2009.03439.x
29. Torales J, Rodríguez H, Ruiz Díaz C, García O. Diagnóstico y
Comorbilidades. En: Torales J, Viola L, Arce A, editores. Guía Esencial de
Tricotilomanía Pediátrica. 1ª ed. Asunción: EFACIM; 2014. p. 19-22.
30. Cather JC, Cather JC. A child with nonscarring alopecia. Proc (Bayl Univ
Med Cent). 2005;18(3): 269-272. URL.
31. Flessner C. Diagnosis and comorbidity. En: Grant J, Stein D, Woods D,
Keuthen N, editores. Trichotillomania, skin picking and other body-
focused repetitive behaviors. Washington DC: American Psychiatric
Publishing; 2012. p. 83-96.
32. Tolin DF, Franklin ME, Diefenbach GJ, Anderson E, Meunier SA.
Pediatric trichotillomania: descriptive psychopathology and an open
trial of cognitive–behavioral therapy. Cogn Behav Ther 2007;36(3):129-
144. https://doi.org/10.1080/16506070701223230
33. Franklin ME, Flessner CA, Woods DW, Keuthen NJ, Piacentini JC,
Moore P et al. The child and adolescent trichotillomania impact project:
descriptive psychopathology, comorbidity, functional impairment, and
treatment utilization. J Dev Behav Pediatr. 2008;29(6):493-500. https://
doi.org10.1097/DBP.0b013e31818d4328
34. Siddappa K. Trichotillomania. Indian J Dermatol Venereol Leprol
2003;69(2):63-68. URL.
35. Franklin ME, Tolin DF. Treating Trichotillomania: Cognitive Behavioral
Therapy for Hair Pulling and Related Problems. Springer Science and
Business Media: New York: 2007.
36. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill
CL et al. The Yale-Brown Obsessive Compulsive Scale. I. Development,
use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006-1011. URL.
37. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger
GR. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen
Psychiatry. 1989;46(11):1012-1016. URL.
38. Torales J, Viola L, Moreno M, Riego V, Villalba J, Ruiz Díaz C. Evaluación.
En: Torales J, Viola L, Arce A, editores. Guía Esencial de Tricotilomanía
Pediátrica. 1ª ed. Asunción: EFACIM; 2014. p. 26-28.
128
39. Torales J. Terapia cognitivo conductual para el tratamiento del trastorno
de excoriación. Revista Argentina de Clínica Psicológica 2018: [Epub
ahead of print]. https://doi.org/10.24205/03276716.2018.1052
40. Arce A, Viola L, Torales J, Riego V, Ruiz Díaz C. Opciones actuales de
tratamiento. En: Torales J, Viola L, Arce A, editores. Guía Esencial de
Tricotilomanía Pediátrica. 1ª ed. Asunción: EFACIM; 2014. p. 29-38.
41. American Academy of Child and Adolescent Psychiatry [Internet].
Aacap.org/; c2013 [cited 06 Nov 2018]. Facts for Families: Hair Pulling
(Trichotillomania), 2013 [approx. 2 screens]. Available from: https://www.
aacap.org/aacap/Families_and_Youth/Facts_for_Families/Facts_for_
Families_Pages/Hair_Pulling_Trichotillomania_96.aspx
42. Figueroa Quintana A, Soutullo Esperón C: Tratamiento farmacológico
de los trastornos de ansiedad en niños y adolescentes. En: Soutullo
Esperón C, editor. Guía Esencial de Psicofarmacología del Niño y del
Adolescente. Madrid: Editorial Médica Panamericana; 2011. p. 211-229.
43. Figueroa Quintana A, Díez Suárez A, Soutullo Esperón C. Tratamiento
farmacológico del trastorno obsesivo compulsivo en niños y adolescentes.
En: Soutullo Esperón C, editor. Guía Esencial de Psicofarmacología del
Niño y del Adolescente. Madrid: Editorial Médica Panamericana; 2011.
p. 231-245.
44. Rothbart R, Amos T, Siegfried N, Ipser JC, Fineberg N, Chamberlain SR
et al. Pharmacotherapy for trichotillomania. Cochrane Database Syst
Rev. 2013;11:CD007662. https://doi.org/10.1002/14651858.CD007662.pub
45. Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator,
in the treatment of trichotillomania: a double-blind, placebo-controlled
study. Arch Gen Psychiatry. 2009;66(7):756-763. https://doi.org/10.1001/
archgenpsychiatry.2009.60
46. Van Ameringen M, Mancini C, Patterson B, Bennett M, Oakman J. A
randomized, double-blind, placebo-controlled trial of olanzapine in the
treatment of trichotillomania. J Clin Psychiatry. 2010;71(10):1336-1343.
https://doi.org/10.4088/JCP.09m05114gre
47. Grant JE, Odlaug BL, Chamberlain SR, Kim SW. Dronabinol, a
cannabinoid agonist, reduces hair pulling in trichotillomania: a pilot
study. Psychopharmacology (Berl). 2011;218(3):493-502. https://doi.
org/10.1007/s00213-011-2347-8
129
6.7. Bibliografía
140
11. Woods DW, Twohig MP. Trichotillomania: An ACT-Enhanced Behavior
Therapy Approach. New York: Oxford University Press; 2008.
12. Teng EJ, Woods DW, Twohig MP. Habit reversal as a treatment for
chronic skin picking. Behav Modif 2006;30(4):411-422. URL.
13. Galasso L [Internet]. Psicoterapia-breve.com.ar; c2017 [cited 07 Nov
2018]. Tricotilomanía [approx. 6 screens]. Available from: http://www.
psicoterapia-breve.com.ar/tricotilomania.php
14. Ortiz R, Ibarra V, Almirón M, González I, Gómez N, Torales J. Fisioterapia
en Salud Mental: una breve guía introductoria. 1ª ed. Asunción: EFACIM;
2018.
15. Beck JS. Cognitive Therapy: Basics and Beyond. New York: Guilford; 1995.
16. Hayes SC, Strosahl KD, Wilson KG. Acceptance and Commitment
Therapy: An Experiential Approach to Behavior Change. New York:
Guilford; 1999.
17. Twohig MP, Hayes SC, Masuda A. A preliminary investigation of
acceptance and commitment therapy as a treatment for chronic skin
picking. Behav Res Ther. 2006;44(10):1513-1522. https://doi.org/10.1016/j.
brat.2005.10.002
18. Flessner CA, Busch AM, Heideman PW, Woods DW. Acceptance-
enhanced behavior therapy (AEBT) for trichotillomania and chronic skin
picking: exploring the effects of component sequencing. Behav Modif.
2008;32(5):579-594. https://doi.org/10.1177/0145445507313800
19. Franklin ME, Zagrabbe K, Benavides KL. Trichotillomania and its
treatment: a review and recommendations. Expert Rev Neurother.
2011;11(8):1165-1174. https://doi.org/10.1586/ern.11.93
20. Franklin ME, Tolin DF. Treating Trichotillomania: Cognitive Behavioral
Therapy for Hair Pulling and Related Problems. Springer Science and
Business Media: New York: 2007.
141
7.9. Bibliografía
154
12. Torales J. Delusional Infestations. In: Bhugra D, Malhi G, eds. Troublesome
disguises: Managing challenging disorders in Psychiatry. 2ª ed. London:
Wiley Blackwell; 2015. p. 252-261. https://doi.org/10.1002/9781118799574
13. Torales Benítez J, Amarilla Vallejo A, García Franco O. Concepto y
epidemiología del trastorno de excoriación. En: Torales Benítez J, editor.
El Trastorno de Excoriación: de la emoción a la lesión. 1ª ed. Asunción:
EFACIM; 2014. p. 41-52.
14. Wojewoda K, Brenner J, Kąkol M, Naesström M, Jerzy Cubała W,
Kozicka D et al. A cry for help, do not omit the signs. Dermatitis
artefacta – psychiatric problems in dermatological diseases (a review of
5 cases). Med Sci Monit. 2012;18(10):CS85-CS89.https://doi.org/10.12659/
MSM.883474
15. Tittelbach J, Peckruhn M, Elsner P. Histopathological patterns in
dermatitis artefacta. J Dtsch Dermatol Ges. 2018;16(5):559-564. https://
doi.org/10.1111/ddg.13504
16. Sneddon I, Sneddon J. Self-inf licted injury: A follow-up study of 43
patients. Br Med J. 1975;3(5982):527-530. URL.
17. Rodriguez-Pichardo A, García-Bravo B, Camacho F. Dermatitis artefacta:
A clinical study. In: Panconesi E, editor. Dermatology in Europe. London:
Blackwel Scientific Publicatons; 1991. p. 866-867.
18. Consoli SG. Dermatitis artefacta: A general review. Eur J Dermatol.
1995;5:5-11.
19. Miguélez Hernández A, Pascual Aranda A, Vanaclocha Sebastian F,
Rubio Valladolid G, Iglesias Diez L. Dermatitis artefacta de localización
periorbitaria y perioral. Actas Dermosifiliogr. 2002;93(1):45-48. URL.
20. Koblenzer CS. The current management of delusional para-sitosis and
dermatitis artefacta. Skin Therapy Lett. 2010;15(9):1-3. URL.
21. Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock’s Synopsis of Psychiatry.
11th ed. Philadelphia: Wolters Kluwer; 2015.
22. Torales J, Di Martino B. Psychodermatology: mind the skin. Telangana
Journal of Psychiatry 2016;2(1):5-7. URL.
23. Rodríguez M, García Contreras SJ. Dermatitis artefacta. Rev Cent
Dermatol Pascua 2010;19(2):59-61. URL.
155
8.9. Bibliografía
170
14. Conceição D, Chagas M, Arzeno Y, Archetti L, Hajaj C, Franklin L, et
al. Body dysmorphic disorder in patients with obsessive-compulsive
disorder: prevalence and clinical correlates. Depress Anxiety.
2012;29(11):966-975.https://doi.org/10.1002/da.21980
15. Phillips KA, Dufresne RG, Wilkel CS, Vittorio CC. Rate of body
dysmorphicdisorder in dermatology patients. J Am Acad Dermatol
2000;42(3):436-441. URL.
16. Sarwer DB, Crerand CE. Psychological issues in patient outcomes. Facial
Plast Surg 2002;18(2):125-133. https://doi.org/10.1055/s-2002-32203
17. Phillips K, Menard W, Fay C. Gender similarities and differences in
200 individuals with body dysmorphic disorder. Compr Psychiatry
2006;47(2):77-87. https://doi.org/10.1016/j.comppsych.2005.07.002
18. Bjornsson A, Didie E, Phillips K. Body dysmorphic disorder. Dialogues
Clin Neurosci. 2010;12(2):221-232. URL.
19. Fang A, Matheny N, Wilhelm S. Body Dysmorphic Disorder. Psychiatr
Clin North Am. 2014 Sep;37(3):287-300. https://doi.org/10.1016/j.
psc.2014.05.003
20. Giraldo-O’Meara M, Belloch A. El trastorno dismórfico corporal:
Un problema infradiagnosticado. Revista de Psicopatología y
Psicología Clínica 2017;22:69-84.https://doi.org/10.5944/rppc.vol.22.
num.1.2017.17929
21. Reese HE, McNally RJ, Wilhelm S. Probabilistic reasoning in patients with
body dysmorphic disorder. J Behav Ther Exp Psychiatry. 2011;42(3):270-
276. https://doi.org/10.1016/j.jbtep.2010.11.005
22. Buhlmann U, Etcoff NL, Wilhelm S. Emotion recognition bias for
contempt and anger in body dysmorphic disorder. J Psychiatr Res.
2006;40(2):105-111. https://doi.org/10.1016/j.jpsychires.2005.03.006
23. Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock’s Synopsis of Psychiatry.
11th ed. Philadelphia: Wolters Kluwer; 2015.
24. Pavan C, Simonato P, Marini M, Mazzoleni F, Pavan L, Vindigni V.
Psychopathologic aspects of body dysmorphic disorder: a literature
review. Aesthetic Plast Surg. 2008;32(3):473-484. https://doi.org/10.1007/
s00266-008-9113-2
25. Hong K, Nezgovorova V, Hollander E. New perspectives in the treatment
of body dysmorphic disorder. F1000Res. 201823;7:361. https://doi.
org/10.12688/f1000research.13700.1
26. Phillips KA, Pagano ME, Menard W, Fay C, Stout RL. Predictors of
remission from body dysmorphic disorder: A prospective study. J Nerv
Ment Dis. 2005;193(8):564-567. URL.
171
27. Johnson S, Williamson P, Wade T. A systematic review and meta-analysis
of cognitive processing deficits associated with body dysmorphic
disorder. Behav Res Ther. 2018;107:83-94. https://doi.org/10.1016/j.
brat.2018.05.013
28. Sandoval M, García-Huidobro I, Pérez-Cotapos ML. Trastorno dismórfi-
co corporal. Rev. Chilena Dermatol. 2009;25(3):244-250. URL.
29. Neziroglu FA, Yaryura-Tobias JA. Exposure, response prevention, and
cognitive therapy in the treatment of body dysmorphic disorder. Behav
Therapy 1993;24(3):431-438. https://doi.org/10.1016/S0005-7894(05)80215-1
30. Torales J, Arce A, Zacarías M, Girala N, Moreno M, Szwako A, et al. La
Guía TAZ de Psicofarmacología Clínica. 1ª ed. Asunción: EFACIM; 2014.
31. Phillips KA, Dufresne RG. Body dysmorphic disorder. A guide for
dermatologists and cosmetic surgeons. Am J Clin Dermatol 2000;1(4):235-
243. https://doi.org/10.2165/00128071-200001040-00005
172
9.9. Bibliografía
1. Greb JE, Goldminz AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ et
al. Psoriasis. Nature Reviews Disease Primers. 2016;2:16082. https://doi.
org/10.1038/nrdp.2016.82
2. Michalek IM, Loring B, John SM. A systematic review of worldwide
epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205-
12. https://doi.org/10.1111/jdv.13854
3. Qureshi AA, Dominguez PL, Choi HK, Han J, Curhan G. Alcohol
intake and risk of incident psoriasis in US women: a prospective
study. Arch Dermatol. 2010;146(12):1364-9. https://doi.org/10.1001/
archdermatol.2010.204
4. Mahil SK, Capon F, Barker JN. Genetics of psoriasis. Dermatol Clin.
2015;33(1):1–11. https://doi.org/10.1016/j.det.2014.09.001
5. Gupta MA, Gupta AK, Kirkby S, Schork NJ, Gorr SK, Ellis CN, et al. A
psychocutaneous profile of psoriasis patients who are stress reactors. A
study of 127 patients. Gen Hosp Psychiatry. 1989;11(3):166-73. https://doi.
org/10.1016/0163-8343(89)90036-4
6. Ros S, Puig L, Carrascosa JM. Discapacidad acumulada en el transcurso
vital: la cicatriz de la psoriasis en la vida del paciente. Actas Dermo-
Sifiliográficas. 2014;105(2):128-34. https://doi.org/10.1016/j.ad.2013.02.009
7. Gupta MA, Gupta AK. Psychiatric and psychological co-morbidity in
patients with dermatologic disorders: epidemiology and management.
Am J Clin Dermatol. 2003;4(12):833-42. https://doi.org/10.2165/00128071-
200304120-00003
8. Mattei PL, Corey KC, Kimball AB. Cumulative life course impairment:
evidence for psoriasis. Curr Probl Dermatol. 2013;44:82-90. https://doi.
org/10.1159/000350008
9. Richards HL, Fortune DG, Griffiths CEM. Adherence to treatment in
patients with psoriasis. J Eur Acad Dermatol Venereol. 2006;20(4):370-9.
https://doi.org/10.1111/j.1468-3083.2006.01565.x
10. Schaaf H, Eipp C, Deubner R, Hesse G, Vasa R, Gieler U. [Psychosocial
aspects of coping with tinnitus and psoriasis patients. A comparative
study of suicidal tendencies, anxiety and depression]. HNO. 2009;57(1):57-
63. https://doi.org/10.1007/s00106-008-1800-4
11. Mizara A, Papadopoulos L, McBride SR. Core beliefs and psychological
distress in patients with psoriasis and atopic eczema attending
secondary care: the role of schemas in chronic skin disease. Br J Dermatol.
2012;166(5):986-93. https://doi.org/10.1111/j.1365-2133.2011.10799.x
194
12. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression,
anxiety, and suicidality in patients with psoriasis: a population-based
cohort study. Arch Dermatol. 2010;146(8):891-5. https://doi.org/10.1001/
archdermatol.2010.186
13. Pompili M, Innamorati M, Forte A, Erbuto D, Lamis DA, Narcisi A, et
al. Psychiatric comorbidity and suicidal ideation in psoriasis, melanoma
and allergic disorders. Int J Psychiatry Clin Pract. 2017;21(3):209-14.
https://doi.org/10.1080/13651501.2017.1301482
14. Gupta MA, Schork NJ, Gupta AK, Kirkby S, Ellis CN. Suicidal
ideation in psoriasis. Int J Dermatol. 1993;32(3):188-90. https://doi.
org/10.1111/j.1365-4362.1993.tb02790.x
15. Singh S, Taylor C, Kornmehl H, Armstrong AW. Psoriasis and
suicidality: A systematic review and meta-analysis. J Am Acad Dermatol.
2017;77(3):425-40. https://doi.org/10.1016/j.jaad.2017.05.019
16. Snast I, Reiter O, Atzmony L, Leshem YA, Hodak E, Mimouni D, et al.
Psychological stress and psoriasis: a systematic review and meta-analysis.
Br J Dermatol. 2018;178(5):1044-55. https://doi.org/10.1111/bjd.16116
17. Picardi A, Abeni D. Stressful life events and skin diseases: disentangling
evidence from myth. Psychother Psychosom. 2001;70(3):118-36.
18. Vasili E. Alcohol Consumption in Patients with Psoriasis and its
Relationship to Disease Severity. Journal of Nutritional Therapeutics
[Internet]. 2013; Available from: https://doi.org/10.6000/1929-
5634.2013.02.01.5
19. McAleer MA, Mason DL, Cunningham S, O’Shea SJ, McCormick PA,
Stone C, et al. Alcohol misuse in patients with psoriasis: identification and
relationship to disease severity and psychological distress. Br J Dermatol.
2011;164(6):1256-61. https://doi.org/10.1111/j.1365-2133.2011.10345.x
20. Vardy D, Besser A, Amir M, Gesthalter B, Biton A, Buskila D. Experiences
of stigmatization play a role in mediating the impact of disease severity
on quality of life in psoriasis patients. Br J Dermatol. 2002;147(4):736-42.
https://doi.org/10.1046/j.1365-2133.2002.04899.x
21. Sampogna F, Gisondi P, Tabolli S, Abeni D, IDI Multipurpose Psoriasis
Research on Vital Experiences investigators. Impairment of sexual life
in patients with psoriasis. Dermatology. 2007;214(2):144-50. https://doi.
org/10.1159/000098574
22. Pompili M, Mancinelli I, Tatarelli R. Stigma as a cause of suicide.
British Journal of Psychiatry. 2003;183(02):173-4. https://doi.org/10.1192/
S0007125000162774
195
23. Eghlileb AM, Davies EEG, Finlay AY. Psoriasis has a major secondary
impact on the lives of family members and partners. Br J Dermatol.
2007;156(6):1245-50. https://doi.org/10.1111/j.1365-2133.2007.07881.x
24. Horn EJ, Fox KM, Patel V, Chiou C-F, Dann F, Lebwohl M. Association
of patient-reported psoriasis severity with income and employment.
J Am Acad Dermatol. 2007;57(6):963-71. https://doi.org/10.1016/j.
jaad.2007.07.023
25. Bhatti ZU, Finlay AY, Bolton CE, George L, Halcox JP, Jones SM, et
al. Chronic disease inf luences over 40 major life-changing decisions
(MLCDs): a qualitative study in dermatology and general medicine. J Eur
Acad Dermatol Venereol. 2014;28(10):1344-55. https://doi.org/10.1111/
jdv.12289
26. Hill L, Kennedy P. The role of coping strategies in mediating subjective
disability in people who have psoriasis. Psychol Health Med. 2002;7(3):261-
9. https://doi.org/10.1080/13548500220139340
27. Scharloo M, Kaptein AA, Weinman J, Bergman W, Vermeer BJ, Rooi-
jmans HGM. Patients’ illness perceptions and coping as predictors
of functional status in psoriasis: a 1-year follow-up. Br J Dermatol.
2000;142(5):899-907. https://doi.org/10.1046/j.1365-2133.2000.03469.x
28. Fortune DG, Richards HL, Griffiths CEM, Main CJ. Targeting cognitive-
behaviour therapy to patients’ implicit model of psoriasis: results from a
patient preference controlled trial. Br J Clin Psychol. 2004;43(Pt1):65-82.
https://doi.org/10.1348/014466504772812977
29. Connor CJ, Liu V, Fiedorowicz JG. Exploring the Physiological
Link between Psoriasis and Mood Disorders. Dermatol Res Pract.
2015;15;2015:409637.
30. Kannan S, Heller MM, Lee ES, Koo JY. The role of tumor necrosis factor-
alpha and other cytokines in depression: what dermatologists should
know. J Dermatolog Treat. 2013;24(2):148-52. https://doi.org/10.3109/095
46634.2011.619159
31. Steptoe A, Hamer M, Chida Y. The effects of acute psychological stress
on circulating inf lammatory factors in humans: a review and meta-
analysis. Brain Behav Immun. 2007;21(7):901-12. https://doi.org/10.1016/j.
bbi.2007.03.011
32. Owens MJ, Nemeroff CB. The Role of Corticotropin-Releasing Factor in
the Pathophysiology of Affective and Anxiety Disorders: Laboratory and
Clinical Studies. In: Novartis Foundation Symposia. 2007. p. 296–316.
196
33. Kim JE, Cho DH, Kim HS, Kim HJ, Lee JY, Cho BK, et al. Expression
of the corticotropin-releasing hormone-proopiomelanocortin axis in
the various clinical types of psoriasis. Exp Dermatol. 2007;16(2):104-9.
https://doi.org/10.1111/j.1600-0625.2006.00509.x
34. Kreibig SD. Autonomic nervous system activity in emotion: A
review. Biol Psychol. 2010;84(3):394-421. https://doi.org/10.1016/j.
biopsycho.2010.03.010
35. Lubahn CL, Lorton D, Schaller JA, Sweeney SJ, Bellinger DL. Targeting
α- and β-Adrenergic Receptors Differentially Shifts Th1, Th2, and
Inf lammatory Cytokine Profiles in Immune Organs to Attenuate
Adjuvant Arthritis. Front Immunol. 2014;11;5:346. https://doi.org/10.3389/
fimmu.2014.00346
36. Dhabhar FS. Effects of stress on immune function: the good, the bad, and
the beautiful. Immunol Res. 2014;58(2-3):193-210. https://doi.org/10.1007/
s12026-014-8517-0
37. Wright CE, Strike PC, Brydon L, Steptoe A. Acute inf lammation and
negative mood: mediation by cytokine activation. Brain Behav Immun.
2005;19(4):345-50. https://doi.org/10.1016/j.bbi.2004.10.003
38. Dunn AJ, Swiergiel AH, de Beaurepaire R. Cytokines as mediators of
depression: what can we learn from animal studies? Neurosci Biobehav
Rev. 2005;29(4-5):891-909. https://doi.org/10.1016/j.neubiorev.2005.03.023
39. Gimeno D, Kivimäki M, Brunner EJ, Elovainio M, De Vogli R, Steptoe
A, et al. Associations of C-reactive protein and interleukin-6 with
cognitive symptoms of depression: 12-year follow-up of the Whitehall
II study. Psychol Med. 2009;39(3):413-23. https://doi.org/10.1017/
S0033291708003723
40. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al.
Etanercept and clinical outcomes, fatigue, and depression in psoriasis:
double-blind placebo-controlled randomised phase III trial. Lancet.
2006;367(9504):29-35. https://doi.org/10.1016/S0140-6736(05)67763-X
41. Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R. The new “5-HT”
hypothesis of depression: Cell-mediated immune activation induces
indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan
and an increased synthesis of detrimental tryptophan catabolites
(TRYCATs), both of which contribute to the onset of depression. Prog
Neuropsychopharmacol Biol Psychiatry. 2011;35(3):702-21. https://doi.
org/10.1016/j.pnpbp.2010.12.017
197
42. Janelidze S, Mattei D, Westrin Å, Träskman-Bendz L, Brundin L.
Cytokine levels inthe blood may distinguish suicide attempters from
depressed patients. Brain Behav Immun. 2011;25(2):3359. https://doi.
org/10.1016/j.bbi.2010.10.010
43. Munzer A, Sack U, Mergl R, Schönherr J, Petersein C, Bartsch
S, et al. Impact of antidepressants on cytokine production of
depressed patients in vitro. Toxins. 2013;5(11):2227-40. https://doi.
org/10.3390%2Ftoxins5112227
44. Carrillo-Vico A, Lardone PJ, Alvarez-Sánchez N, Rodríguez-Rodríguez
A, Guerrero JM. Melatonin: buffering the immune system. Int J Mol Sci.
2013;14(4):8638-83. https://doi.org/10.3390/ijms14048638
45. Kartha LB, Chandrashekar L, Rajappa M, Menon V, Thappa DM, Anan-
thanarayanan PH. Serum melatonin levels in psoriasis and associated
depressive symptoms. Clin Chem Lab Med. 2014;52(6):e123-5. https://doi.
org/10.1515/cclm-2013-0957
46. Hung M-W, Kravtsov GM, Lau C-F, Poon AM-S, Tipoe GL, Fung M-L.
Melatonin ameliorates endothelial dysfunction, vascular inf lammation,
and systemic hypertension in rats with chronic intermittent hypoxia. J
Pineal Res. 2013;55(3):247-56. https://doi.org/10.1111/jpi.12067
47. Torales J, Arce A, Chávez E, Melgarejo O. Trastornos depresivos: de la
etiopatogenia a la terapéutica. 1ª ed. Asunción: EFACIM; 2018.
48. Merola JF, Li T, Li W-Q, Cho E, Qureshi AA. Prevalence of psoriasis
phenotypes among men and women in the USA. Clin Exp Dermatol.
2016;41(5):486-9. https://doi.org/10.1111/ced.12805
49. Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaçi D, Behrens
F, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis
in patients with psoriasis in European/North American dermatology
clinics. J Am Acad Dermatol. 2013;69(5):729-35. https://doi.org/10.1016/j.
jaad.2013.07.023
50. Korman AM, Hill D, Alikhan A, Feldman SR. Impact and management
of depression in psoriasis patients. Expert Opin Pharmacother.
2016;17(2):147-52. https://doi.org/10.1517/14656566.2016.1128894
51. Menter A, Griffiths CEM. Current and future management of
psoriasis. Lancet. 2007;370(9583):272-84. https://doi.org/10.1016/S0140-
6736(07)61129-5
52. Kimball A, Sundaram M, Hudgen S. Evaluation of cumulative life course
impairment in psoriasis: A qualitative study. J Am Acad Dermatol.
2013;68(4):AB200. https://doi.org/10.1016/j.jaad.2012.12.826
198
53. Fortune DG, Richards HL, Kirby B, Bowcock S, Main CJ, Griffiths CEM.
A cognitive-behavioural symptom management programme as an
adjunct in psoriasis therapy. Br J Dermatol. 2002;146(3):458-65. https://
doi.org/10.1046/j.1365-2133.2002.04622.x
54. Vezmar S, Becker A, Bode U, Jaehde U. Biochemical and Clinical Aspects
of Methotrexate Neurotoxicity. Chemotherapy. 2003;49(1-2):92–104.
https://doi.org/10.1159/000069773
55. Wu C-Y, Chang Y-T, Juan C-K, Shen J-L, Lin Y-P, Shieh J-J, et al. Depression
and Insomnia in Patients With Psoriasis and Psoriatic Arthritis Taking
Tumor Necrosis Factor Antagonists. Medicine . 2016;95(22):e3816. https://
doi.org/10.1097/MD.0000000000003816
56. Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, et al.
The effect of adalimumab on reducing depression symptoms in patients
with moderate to severe psoriasis: a randomized clinical trial. J Am Acad
Dermatol. 2010;62(5):812-8. https://doi.org/10.1016/j.jaad.2009.07.022
57. Feldman SR, Gottlieb AB, Bala M, Wu Y, Eisenberg D, Guzzo C, et
al. Inf liximab improves health-related quality of life in the presence
of comorbidities among patients with moderate-to-severe psoriasis.
Br J Dermatol. 2008;159(3):704-10. https://doi.org/10.1111/j.1365-
2133.2008.08727.x
58. Bortolato B, Carvalho AF, Soczynska JK, Perini GI, McIntyre RS. The
Involvement of TNF-α in Cognitive Dysfunction Associated with Major
Depressive Disorder: An Opportunity for Domain Specific Treatments.
Curr Neuropharmacol. 2015;13(5):558-76. https://doi.org/10.2174/157015
9X13666150630171433
59. Kim S-J, Park M-Y, Pak K, Han J, Kim G-W, Kim H-S, et al. Improvement
of depressive symptoms in patients with moderate-to-severe psoriasis
treated with ustekinumab: an open label trial validated using beck
depression inventory, Hamilton depression rating scale measures and
18f luorodeoxyglucose (FDG) positron emission tomography (PET). J
Dermatolog Treat. 2018;1-8. https://doi.org/10.1080/09546634.2018.14660
21
60. Griffiths CEM, Fava M, Miller AH, Russell J, Ball SG, Xu W, et al. Impact
of Ixekizumab Treatment on Depressive Symptoms and Systemic
Inf lammation in Patients with Moderate-to-Severe Psoriasis: An
Integrated Analysis of Three Phase 3 Clinical Studies. Psychother
Psychosom. 2017;86(5):260-7. https://doi.org/10.1159/000479163
199
10.9. Bibliografía
216
12. Giachetti A, Greco MF, Scacchi MF, Flores RM, Castro C. Consenso
Nacional de Dermatitis Atópica 2013. Sociedad Argentina de Pediatría:
Buenos Aires; 2013. https://doi.org/10.5546/aap.2014.e195
13. Ji H, Li XK. Oxidative Stress in Atopic Dermatitis. Oxid Med Cell Longev.
2016;2016:2721469. https://doi.org/10.1155/2016/2721469
14. Cabanillas-Becerra JJ, Sánchez-Saldaña L. Dermatitis atópica. Dermatol
Peru. 2012;22 (3):176-186. URL.
15. Picone Z, Woscoff A, Maccario MF, Troielli P, Luna L, Fligler F.
Etiopatogenia. En: Pueyo S, García MA, García Diaz R, Castro C,
editores. Consenso Nacional de Dermatitis Atópica. Sociedad Argentina
de Dermatología: Buenos Aires; 2004. p. 6-9. URL.
16. Sánchez J, Páez B, Macías A, Olmos C, de Falco A. Atopic dermatitis
guideline. Position paper from the Latin American Society of Allergy,
Asthma and Immunology. Rev Alerg Mex. 2014;61(3):178-211. URL.
17. Nygaard U, Vestergaard C, Deleuran M. Emerging Treatment Options in
Atopic Dermatitis: Systemic Therapies. Dermatology. 2017;233(5):344-357.
https://doi.org/10.1159/000484406
18. Senra MS, Wollenberg A. Psychodermatological aspects of atopic
dermatitis. Br J Dermatol. 2014;170(Suppl 1):38-43. https://doi.
org/10.1111/bjd.13084
19. Lee S, Shin A. Association of atopic dermatitis with depressive symptoms
and suicidal behaviors among adolescents in Korea: the 2013 Korean
Youth Risk Behavior Survey. BMC Psychiatry. 2017;17(1):3. https://doi.
org/10.1186/s12888-016-1160-7
20. Nicholas MN Gooderham MJ. Atopic Dermatitis, Depression,
and Suicidality. J Cutan Med Surg. 2017;21(3):237-242. https://doi.
org/10.1177/1203475416685078
21. Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-
Wagner A et al. Consensus-based European guidelines for treatment of
atopic eczema (atopic dermatitis) in adults and children: part II. J Eur
Acad Dermatol Venereol. 2018;32(6):850-878. https://doi.org/10.1111/
jdv.14888
22. Gonzalez E, Sanguino RM, Franco MA. Bupropion in atopic dermatitis.
Pharmacopsychiatry.2006;39(6):229. URL.
23. Modell JG, Boyce S, Taylor E, Katholi C. Treatment of atopic dermatitis
and psoriasis vulgaris with bupropion-SR: a pilot study. Psychosom Med.
2002;64(5):835-840. URL.
24. Altschuler EL, Kast RE. Bupropion in psoriasis and atopic dermatitis:
decreased tumor necrosis factor-alpha? Psychosom Med. 2003;65(4):719.
URL.
217
25. Kast RE. Evidence of a mechanism by which etanercept increased TNF-
alpha in multiple myeloma: new insights into the biology of TNF-alpha
giving new treatment opportunities – the role of bupropion. Leuk Res.
2005; 29(12):1459-1463. https://doi.org(10.1016/j.leukres.2005.05.006
26. Chida Y, Steptoe A, Hirakawa N, Sudo N, Kubo C. The effects of
psychological intervention on atopic dermatitis. A systematic review
and meta-analysis. Int Arch Allergy Immunol. 2007;144(1):1-9. https://doi.
org/10.1159/000101940
27. Ehlers A, Stangier U, Gieler U. Treatment of atopic dermatitis: a
comparison of psychological and dermatological approaches to relapse
prevention. J Consult Clin Psychol. 1995;63(4):624-635. URL.
28. Melin L, Frederiksen T, Noren P, Swebilius BG. Behavioural treatment
of scratching in patients with atopic dermatitis. Br J Dermatol.
1986;115(4):467-474.URL.
29. Noren P, Melin L. The effect of combined topical steroids and habit-
reversal treatment in patients with atopic dermatitis. Br J Dermatol.
1989; 121(3):359-366. URL.
30. Torales J. Terapia cognitivo conductual para el tratamiento del trastorno
de excoriación. Revista Argentina de Clínica Psicológica 2018: [Epub
ahead of print]. https://doi.org/10.24205/03276716.2018.1052
218
11.9. Bibliografía
235
14. Kaminsky A, Ramos-e-Silva M, Costantini S. Erupciones acneiformes.
En: Kaminsky A, Flórez-White M, editoras. Acné. Un enfoque global. 3ª
ed. Buenos Aires: Colegio Ibero-Latinoamericano de Dermatología; 2015.
p. 108-120.
15. Torales Benítez J, Rodríguez Marín H. Diagnóstico y evaluación del
trastorno de excoriación. En: Torales Benítez J, editor. El Trastorno de
Excoriación: de la emoción a la lesión. 1ª ed. Asunción: EFACIM; 2014. p.
79-90.
16. American Psychiatric Association. Diagnostic and Statistical Manual
of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric
Publishing; 2013.
17. Troielli, P. Diagnóstico diferencial. En: Kaminsky A, Flórez-White M,
editoras. Acné. Un enfoque global. 3ª ed. Buenos Aires: Colegio Ibero-
Latinoamericano de Dermatología; 2015. p. 121-127.
18. Díez de Medina JC. Adherencia al tratamiento. En: Kaminsky A, Flórez-
White M, editoras. Acné. Un enfoque global. 3ª ed. Buenos Aires: Colegio
Ibero-Latinoamericano de Dermatología; 2015. p. 308-312.
19. Flórez-White M. Cuidados dermocosméticos. En: Kaminsky A, Flórez-
White M, editoras. Acné. Un enfoque global. 3ª ed. Buenos Aires: Colegio
Ibero-Latinoamericano de Dermatología; 2015. p. 295-307.
20. Giachetti A. Acné. Conceptos actuales. Buenos Aires: Sociedad Argentina
de Pediatría; 2008. URL.
21. Ferreira Alves G. Tratamiento tópico. En: Kaminsky A, editora. Acné. Un
enfoque global. 1ª ed. Buenos Aires: Colegio Ibero-Latinoamericano de
Dermatología; 2007. p. 71-100.
22. Bagatin E. Tratamiento sistémico 2. Isotretinoína. En: Kaminsky A, Fló-
rez-White M, editoras. Acné. Un enfoque global. 3ª ed. Buenos Aires: Co-
legio Ibero-Latinoamericano de Dermatología; 2015. p. 176-196.
23. Grupo Ibero-Latinoamericano de Estudio del Acné. Algoritmo de trata-
miento. En: Kaminsky A, Flórez-White M, editoras. Acné. Un enfoque
global. 3ª ed. Buenos Aires: Colegio Ibero-Latinoamericano de Derma-
tología; 2015. p. 261-262.
236
12.9. Bibliografía
1. Troielli P, González Otero FM, Ríos Yuil JM, Vázquez Martínez OT,
Pabón Montoya JG, Ibarra M et al. Actualización y recomendaciones
para el diagnóstico y tratamiento de la rosácea en Latinoamérica. Med
Cutan Iber Lat Am 2016;44(S1):S7-S26. URL.
2. Grupo Ibero-Latinoamericano de Estudio de la Rosácea (GILER) – CILAD.
Informe de Consenso Ibero-Latinoamericano 2016 sobre la clasificación
clínica y terapéutica de la rosácea. Med Cutan Iber Lat Am 2016;44(1):6-
10. URL.
3. Plewig G. Rosácea. En: Fitzpatrick T, editor. Dermatología en Medicina
General. 4a ed. Buenos Aires: Médica Panamericana; 1997. p: 762-771.
4. Crawford G, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and
subtype classification. J Am Acad Dermatol. 2004;51(3):327-41. https://
doi.org/10.1016/j.jaad.2004.03.030
5. García García SC. Patogenia. Genética. En: Rosental de Kaminsky A,
Piquero Martín J, Herane M, Diez de Medina J, Flórez-White M. Rosácea:
una visión integral. 1ª ed. CABA: Juan A Sosa; 2018. p. 78-80.
6. Steiner D. Calidad de vida. En: Rosental de Kaminsky A, Piquero Martín
J, Herane M, Diez de Medina J, Flórez-White M. Rosácea: una visión
integral. 1ª ed. CABA: Juan A Sosa; 2018. p. 378-382.
7. Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R et al.
Standard classification of rosacea: Report of the National Rosacea
Society Expert Committee on the Classification and Staging of Rosacea.
J Am Acad Dermatol. 2002;46(4):584-7. URL.
8. Halioua B, Cribier B, Frey M, Tan J. Feelings of stigmatization in patients
with rosacea. J Eur Acad Dermatol Venereol. 2017;31(1):163-168. https://
doi.org/10.1111/jdv.13748
9. Mikkelsen CS, Holmgren HR, Kjellman P, Heidenheim M, Kappinnen A,
Bjerring P et al. Rosacea: a Clinical Review. Dermatol Reports. 2016; 8(1):
6387. https://doi.org/10.4081/dr.2016.6387
10. Tan J, Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol.
2013;69(6 Suppl 1):S27-S35. https://doi.org/10.1016/j.jaad.2013.04.043
11. Flórez-White M. Patogenia. Barrera cutánea y rosácea. En: Rosental
de Kaminsky A, Piquero Martín J, Herane M, Diez de Medina J, Flórez-
White M. Rosácea: una visión integral. 1ª ed. CABA: Juan A Sosa; 2018.
p. 76-78.
12. Tan J, Robledo Prada MA. Flushing y blushing, diagnóstico y manejo. En:
Rosental de Kaminsky A, Piquero Martín J, Herane M, Diez de Medina J,
Flórez-White M. Rosácea: una visión integral. 1ª ed. CABA: Juan A Sosa;
2018. p. 12-23.
254
13. Herane MI, Gomez M. Patogenia. Resumen. En: Rosental de Kaminsky A,
Piquero Martín J, Herane M, Diez de Medina J, Flórez-White M. Rosácea:
una visión integral. 1ª ed. CABA: Juan A Sosa; 2018. p. 101-108.
14. Kaminsky A, Herane MI. Formas clínicas. En: Rosental de Kaminsky A,
Piquero Martín J, Herane M, Diez de Medina J, Flórez-White M. Rosácea:
una visión integral. 1ª ed. CABA: Juan A Sosa; 2018. p. 115-132.
15. Herane M. Generalidades. En: Rosental de Kaminsky A, Piquero Martín
J, Herane M, Diez de Medina J, Flórez-White M. Rosácea: una visión in-
tegral. 1ª ed. CABA: Juan A Sosa; 2018. p. 67-71.
16. Kaminsky A, Flórez-White M, Piquero Martín J, Herane M, Diez de Me-
dina JC. Clasificación nosológica y grado de severidad. En: Rosental de
Kaminsky A, Piquero Martín J, Herane M, Diez de Medina J, Flórez-White
M. Rosácea: una visión integral. 1ª ed. CABA: Juan A Sosa; 2018. p. 110-114.
17. Boente MC, Fiandrino MJ. Formas especiales. Rosácea infantil. En: Ro-
sental de Kaminsky A, Piquero Martín J, Herane M, Diez de Medina J,
Flórez-White M. Rosácea: una visión integral. 1ª ed. CABA: Juan A Sosa;
2018. p. 146-153.
18. Kaminsky A. Formas especiales. Rosácea extrafacial. En: Rosental de
Kaminsky A, Piquero Martín J, Herane M, Diez de Medina J, Flórez-
-White M. Rosácea: una visión integral. 1ª ed. CABA: Juan A Sosa; 2018.
p. 153-157.
19. Pérez Alfonzo R, Giansante E, Patiño Guinand P. Rosácea granuloma-
tosa. En: Rosental de Kaminsky A, Piquero Martín J, Herane M, Diez de
Medina J, Flórez-White M. Rosácea: una visión integral. 1ª ed. CABA:
Juan A Sosa; 2018. p. 158-166.
20. Maroñas-Jiménez L, González-Guerra E, Guerra-Tapia A. Diagnósticos
diferenciales. En: Rosental de Kaminsky A, Piquero Martín J, Herane M,
Diez de Medina J, Flórez-White M. Rosácea: una visión integral. 1ª ed.
CABA: Juan A Sosa; 2018. p. 171-177.
21. Flórez-White M. Medidas generales. En: Rosental de Kaminsky A, Pi-
quero Martín J, Herane M, Diez de Medina J, Flórez-White M. Rosácea:
una visión integral. 1ª ed. CABA: Juan A Sosa; 2018. p. 279-281.
22. Schaller M, Almeida LM, Bewley A, Cribier B, Dlova NC, Kautz G et al.
Rosacea treatment update: recommendations from the global ROSacea
COnsensus (ROSCO) panel. Br J Dermatol. 2017;176(2):465-4471. https://
doi.org/10.1111/bjd.15173
23. Grupo Ibero-Latinoamericano del Estudio de la Rosácea (GILER). Guía
de tratamiento. En: Rosental de Kaminsky A, Piquero Martín J, Herane
M, Diez de Medina J, Flórez-White M. Rosácea: una visión integral. 1ª ed.
CABA: Juan A Sosa; 2018. p. 348-350.
255
13.9. Bibliografía
267
13. Misery L, Rousset H. Is alopecia areata a psychosomatic disease? Rev.
Med. Interne 2001;22(3):274-279. URL.
14. Güleç AT, Tanriverdi N, Dürü C, Saray Y, Akçali C. The role of
psychological factors in alopecia areata and the impact of the disease
on the quality of life. Int J Dermatol. 2004;43(5):352-356. https://doi.or-
g/10.1111/j.1365-4632.2004.02028.x
15. Garzorz N, Alsisi M, Todorova A, Atenhan A, Thomas J, Lauffer F1 et al.
Dissecting susceptibility from exogenous triggers: the model of alopecia
areata and associated inf lammatory skin diseases. J Eur Acad Dermatol
Venereol. 2015;29(12):2429-2435. https://doi.org/10.1111/jdv.13325
16. Ito T. Hair follicle is a target of stress hormone and autoimmune
reactions. J Dermatol Sci. 2010;60(2):67-73. https://doi.org/10.1016/j.
jdermsci.2010.09.006
17. Siebenhaar F, Sharov AA, Peters EM, Sharova TY, Syska W, Mardaryev
AN et al. Substance P as an immunomodulatory neuropeptide in a mouse
model for autoimmune hair loss (alopecia areata). J Invest Dermatol.
2007;127(6):1489-1497. https://doi.org/10.1038/sj.jid.5700704
18. Chu SY, Chen YJ, Tseng WC, Lin MW, Chen TJ, Hwang CY et al.
Comorbidity profiles among patients with alopecia areata: the importance
of onset age, a nationwide population-based study. J Am Acad Dermatol.
2011;65(5):949-956. https://doi.org/10.1016/j.jaad.2010.08.032
19. Huang KP, Mullangi S, Guo Y, Qureshi AA. Autoimmune, atopic, and
mental health comorbid conditions associated with alopecia areata in
the United States. JAMA Dermatol. 2013 Jul;149(7):789-794. https://doi.
org/10.1001/jamadermatol.2013.3049
20. Fernández Bussy (h) R, Macoc M, Vadala MV, Garrido MG, Squeff M,
Fernández Bussy RA. Alopecia areata y enfermedades asociadas: nues-
tra experiencia sobre 265 casos. Arch. Argent. Dermatol. 2014;64(4):134-
138. URL.
21. Colon EA, Popkin MK, Callies AL, Dessert NJ, Hordinsky MK. Lifetime
prevalence of psychiatric disorders in patients with alopecia areata.
Compr Psychiatry. 1991;32(3):245-251. https://doi.org/10.1016/0010-
440X(91)90045-E
22. Bilgiç Ö, Bilgiç A, Bahalı K, Bahali AG, Gürkan A, Yılmaz S. Psychiatric
symptomatology and health-related quality of life in children and
adolescents with alopecia areata. J Eur Acad Dermatol Venereol.
2014;28(11):1463-1468. https://doi.org/10.1111/jdv.12315
23. Hunt N, McHale S. The psychological impact of alopecia. BMJ.
2005;331:951-953. https://doi.org/10.1136/bmj.331.7522.951
268
24. Tucker P. Bald is beautiful? The psychosocial impact of
alopecia areata. J Health Psychol. 2009;14(1):142-151. https://doi.
org/10.1177/1359105308097954
25. Layegh P, Arshadi H, Shahriari S, Pezeshkpour F, Nahidi Y. A
comparative study on the prevalence of depression and suicidal ideation
in dermatology patients suffering from Psoriasis, Acne, Alopecia areata
and Vitiligo. Iran J Dermatol. 2010;13:106-111. URL.
26. Cordan Yazici A, Başterzi A, Tot Acar S Üstünsoy D, Ikizoglu G,
Demirseren D et al. Alopecia areata and alexithymia. Turk Psikiyatri
Dergisi. 2006;17(2):101-106. URL.
27. Arce A, Torales J, Gómez N, Maggi C, editores. La exploración
psicopatológica: una introducción a la semiología psiquiátrica. 1ª ed.
Asunción: EFACIM; 2017.
28. Gokalp H. Psychosocial Aspects of Hair Loss. En: Kutlubay Z, editor.
Hair and Scalp Disorders. 1st ed. London: IntechOpen; 2017. p. 239-252.
29. Bandura A, Reese L, Adams NE. Microanalysis of action and fear arousal
as a function of differential levels of perceived self-efficacy. J Pers Soc
Psychol. 1982;43(1):5-21. URL.
30. Gandhi V, Baruah MC, Bhattacharaya SN. Nail changes in alopecia
areata: incidence and pattern. Indian J Dermatol Venereol Leprol. 2003;
69(2):114-115. URL.
31. Kasumagic-Halilovic E, Prohic A. Nail changes in alopecia areata:
frequency and clinical presentation. J Eur Acad Dermatol Venereol. 2009
Feb;23(2):240-1. https://doi.org/10.1111/j.1468-3083.2008.02830.x
32. Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia
areata update: part I. Clinical picture, histopathology, and pathogenesis.
J Am Acad Dermatol. 2010;62(2):177-88. https://doi.org/10.1016/j.
jaad.2009.10.032
33. Rudnicka L, Olszewska M, Rakowska A, Czuwara J. Atlas of Trichoscopy:
Dermoscopy in hair and scalp disease. 1st ed. London: Springer; 2012.
34. Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol.
2000;42(2):549-566. URL.
35. Lee S, Kim BJ, Lee CH, Lee WS. Increased prevalence of vitamin D
deficiency in patients with alopecia areata: a systematic review and
meta-analysis. J Eur Acad Dermatol Venereol. 2018;32(7):1214-1221.
https://doi.org/10.1111/jdv.14987
36. Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano
AM et al. Alopecia areata: An appraisal of new treatment approaches
and overview of current therapies. J Am Acad Dermatol. 2018;78(1):15-24.
https://doi.org/10.1016/j.jaad.2017.04.1142
269
37. Grimalt R. Aspectos psicológicos de la alopecia areata. En: Grimalt F,
Cotterill J, editores. Dermatología y Psiquiatría. Madrid: Aula Médica
Ediciones; 2002. p. 277-285.
38. Garg S, Messenger AG. Alopecia areata : evidence based treatments.
Semin Cutan Med Surg. 2009;28(1):15-18. https://doi.org/10.1016/j.
sder.2008.12.002
39. Sawant N, Chikhalkar S, Mehta V, Ravi M, Madke B, Khopkar U.
Androgenetic alopecia: quality of life and associated lifestyle patterns.
Int J Trichology. 2010;2(2):81-85. https://doi.org/10.4103/0974-7753.77510
40. Willemsen R, Haentjens P, Roseeuw D, Vanderlinden J. Hypnosis and
alopecia areata: long term beneficial effects on psychological well being.
Acta Derm Venereol. 2011;91(1):35-39. https://doi.org/10.2340/00015555-
1012
41. Prickitt J, McMichael AJ, Gallagher L, Kalabokes V, Boeck C. Helping
patients cope with chronic alopecia areata. Dermatol Nurs 2004;16(3):237-
41. URL.
42. Sehgal VN, Srivastava G, Aggarwal A, Sethi G, Adhikari T. Alopecia
areata in the Indian subcontinent. Skinmed 2007;6(2):63-69. URL.
270
14.4. Bibliografía
283
15.7. Bibliografía
301
22. Sivak R, Wiater A, y Lolas F. Alexitimia, la dificultad para verbalizar
afectos. Buenos Aires: Paidós; 1997.
23. Yalom I. Psicoterapia existencial y terapia de grupo. Buenos Aires:
Paidós; 2000.
24. Zukerfeld R. Psicoanálisis actual: tercera tópica, vulnerabilidad y
contexto social. Revista Internacional de Psicoanálisis Aperturas 2009;2.
302
16.5. Bibliografía
318
14. Crerand CE, Menard W, Phillips KA. Surgical and minimally invasive
cosmetic procedures among persons with body dysmorphic disorder. Ann
Plast Surg. 2010;65(1):11. https://doi.org/10.1097/SAP.0b013e3181bba08f
15. Ipser JC, Sander C, Stein DJ. Pharmacotherapy and psychotherapy for
body dysmorphic disorder. Cochrane Database Systematic Reviews 2009.
Issue 1. Art No.: CD005332. https://doi.org/10.1002/14651858.CD005332.
pub2
16. Phillips KA, Albertini RS, Rasmussen SA. A randomized placebo-
controlled trial of f luoxetine in body dysmorphic disorder. Arch Gen
Psychiatry. 2002 Apr;59(4):381-8. URL
17. Phillips KA, Hollander E. Treating body dysmorphic disorder with
medication: evidence, misconceptions, and a suggested approach. Body
Image. 2008;5(1):13-27. https://doi.org/10.1016/j.bodyim.2007.12.003
18. Phillips KA. Pharmacotherapy for Body Dysmorphic Disorder.
Psychiatr Ann. 2010;40(7):325. https://doi.org/10.3928/00485713-
20100701-05
19. Saxena S, Winograd A, Dunkin JJ. A retrospective review of clinical
characteristics and treatment response in body dysmorphic
disorder versus obsessive‐compulsive disorder. Journal of Clinical
Psychiatry 2001;62:67‐72. URL
20. Escalas J, Guerra A, Rodríguez-Cerdeira M. Tratamiento con
psicofármacos de los trastornos psicodermatológicos. Actas
Dermo-Sifiliográficas. 2010;101(6):485-494. https://doi.org/10.1016/j.
ad.2009.12.027
21. Jafferany M, Vander Stoep A, Dumitrescu A, Hornung RL. The
knowledge, awareness, and practice patterns of dermatologists
toward psychocutaneous disorders: results of a survey study.
Int J Dermatol 2010;49(7):784-789. https://doi.org/10.1111/j.1365-
4632.2009.04372.x
22. Odlaug BL, Hampshire A, Chamberlain SR, Grant JE. Abnormal brain
activation in excoriation (skin-picking) disorder: evidence from an
executive planning fMRI study. Br J Psychiatry. 2016;208(2):168-174.
https://doi.org/10.1192/bjp.bp.114.155192
23. Chamberlain SR, Menzies LA, Fineberg NA, Del Campo N, Suckling
J, Craig K et al. Grey matter abnormalities in trichotillomania:
morphometric magnetic resonance imaging study. Br J Psychiatry.
2008;193(3):216-221. https://doi.org/10.1192/bjp.bp.107.048314
24. Koo JY, Ng TC. Psychotropic and neurotropic agents in dermatology:
unapproved uses, dosages, or indications. Clin Dermatol. 2002;20(5):582-
584. URL
319
25. Torales Benítez J, Girala Salomón N. Farmacoterapia del trastorno de
excoriación. En: Torales Benítez J, editor. El Trastorno de Excoriación:
de la emoción a la lesión. 1ª ed. Asunción: EFACIM; 2014. p. 101-108.
26. Jafferany M, Osuagwu F. Use of Topiramate in Skin-Picking Disorder.
Prim Care Companion CNS Disord 2017;19(1):16m01961. https://doi.
org/10.4088/PCC.16m01961
27. Grant J. PT619. A Double-Blind, Placebo-Controlled Trial of
N-Acetyl Cysteine in the Treatment of Excoriation Disorder. Int J
Neuropsychopharmacol. 2016;19(Suppl 1):27. https://doi.org/10.1093/ijnp/
pyw044.619
28. Grant J, Chamberlain S, Redden S, Leppink E, Odlaug B, Kim
S. N-Acetylcysteine in the Treatment of Excoriation Disorder.
JAMA Psychiatry. 2016;73(5):490-496. https://doi.org/10.1001/
jamapsychiatry.2016.0060
29. Rothbart R, Amos T, Siegfried N, Ipser J, Fineberg N, Chamberlain S et
al. Pharmacotherapy for trichotillomania. Cochrane Database Syst Rev.
2013;(11):CD007662. https://doi.org/10.1002/14651858.CD007662.pub2
30. Naveed S, Amray A, Waqas A, Chaudhary AM, Azeem MW. Use of
N-Acetylcysteine in Psychiatric Conditions among Children and
Adolescents: A Scoping Review. Cureus. 2017;9(11):e1888. https://doi.
org/10.7759/cureus.1888.
31. Kim D, Ryba NL, Kalabalik J, Westrich L. Critical Review of the Use
of Second-Generation Antipsychotics in Obsessive–Compulsive
and Related Disorders. Drugs in R&D. 2018;18(3):167-189. https://doi.
org/10.1007/s40268-018-0246-8
32. Bloch M, Landeros-Weisenberger A, Dombrowski P, Kelmendi B, Wegner
R, Nudel J et al. Systematic Review: Pharmacological and Behavioral
Treatment for Trichotillomania. Biological Psychiatry. 2007;62(8):839-
846. https://doi.org/ 10.1016/j.biopsych.2007.05.019
33. Patel V, Koo JY. Delusions of Parasitosis; Suggested Dialogue between
Dermatologist and Patient. J Dermatolog Treat. 2015;26(5):456-460.
https://doi.org/10.3109/09546634.2014.996513
34. Mercan S, Altunay I, Taskintuna N, Ogutcen O, Kayaoğlu S. Atypical
Antipsychotic Drugs in the Treatment of Delusional Parasitosis. The
International Journal of Psychiatry in Medicine. 2007;37(1):29-37. https://
doi.org/10.2190/M8M5-H1G2-1257-2017
35. Freudenmann R, Lepping P, Huber M, Dieckmann S, Bauer-Dubau
K, Ignatius R et al. Delusional infestation and the specimen sign: a
European multicentre study in 148 consecutive cases. British Journal
of Dermatology. 2012;167(2):247-251. https://doi.org/10.1111/j.1365-
2133.2012.10995.x
320
36. Suh K, Keystone J. Treatment of delusional infestation. In Marder S,
Stratman, eds. Uptodate. Waltham, Massachusetts. Uptodate. 2018.
Disponible en: URL
37. Torales J. Delusional Infestations. In: Bhugra D, Malhi G, eds. Troublesome
disguises: Managing challenging disorders in Psychiatry. 2ª ed. London:
Wiley Blackwell; 2015. p. 252-261. https://doi.org/10.1002/9781118799574
38. Lepping P, Russell I, Freudenmann R. Antipsychotic treatment of primary
delusional parasitosis. British Journal of Psychiatry. 2007;191(03):198-205.
https://doi.org/10.1192/bjp.bp.106.029660
39. Assalman I, Bewley AP, Alhajjar R, Ahmed A, Taylor R. Treatments
for primary delusional infestation. Cochrane Database of
Systematic Reviews 2014, Issue 10. Art. No.: CD011326. https://doi.
org/10.1002/14651858.CD011326.
40. Bennassar A, Guilabert A, Alsina M, Pintor L, Mascaro JM Jr. Treatment of
delusional parasitosis with aripiprazole. Arch Dermatol. 2009;145(4):500-
501. https://doi.org/ 10.4103/0972-6748.98422
41. Freudenmann R, Lepping P. Delusional Infestation. Clinical Microbiology
Reviews. 2009;22(4):690-732. https://doi.org/ 10.1128/CMR.00018-09
42. Rodríguez Pichardo A, García Bravo B. Dermatitis artefacta:
revisión. Actas Dermo-Sifiliográficas. 2013;104(10):854-866. https://doi.
org/10.1016/j.ad.2012.10.004
43. Mohandas P, Bewley A, Taylor R. Dermatitis artefacta and artefactual
skin disease: the need for a psychodermatology multidisciplinary team
to treat a difficult condition. Br J Dermatol. 2013 Sep. 169(3):600-606.
https://doi.org/ 10.1111/bjd.12416
44. Kępska A, Majtyka M, Kowman M, Kłoszewska I, Kwiecińska
E, Zalewska-Janowska A. Dermatitis artefacta as a symptom of
schizophrenia? Advances in Dermatology and Allergology/Postȩpy
Dermatologii i Alergologii. 2014;31(4):277-279. https://doi.org/ 10.5114/
pdia.2014.40921.
321
Otras títulos publicados por
la Editorial de la Facultad de Ciencias Médicas
El Trastorno de Excoriación:
El Libro Azul de la Psiquiatría
de la emoción a la lesión
Servando E. Marrón, MD
Doctor en Medicina y Cirugía, Dermatólogo, Hospital Universitario Miguel Servet,
Zaragoza, España
Investigador Principal del Grupo Aragonés de Investigación en Psicodermatología
(GAI+PD), Zaragoza, España
Coordinador Nacional del Grupo Español de Investigación en Dermatología y
Psiquiatría (GEDEPSI) de la Academia Española de Dermatología y Venereología
(AEDV), Madrid, España
Miembro Titular del Colegio Ibero-Latinoamericano de Dermatología (CILAD)
ISBN 978-99953-67-21-3
ISBN 978-99953-67-21-3
9 789995 367213